• Successful launch and financing of our first company spin-off in the fields of Bio-Defense and Bio-Security developed from our CADI discovery process. PHERECYDES Pharma S.A. (anti-bacterial bio-agents) was incorporated and financed on December 20, 2006.
• Start of our first “white biotech*” collaborative research program (Synthons: bio-production of chemical entities) in the word class white biotech cluster in France (Industry Agro-Resources).
• Delivery of our second research contract CADI™ model in the CNS field (Alzheimer) 
• Delivery of our of first “white biotech*” CADI™ model
• Independent in-vivo experimental validation of a further two CADI™ models: :
  1. Mechanisms of Creutzfeld-Jacob (mad cow, prion) disease pathogenesis, and
  2. Mechanisms of Müllerian duct regression (embryological differentiation)

• Publication of “Biological modeling in the discovery and validation of cognitive dysfunctions biomarkers" in a book edited by the Max Planck Institute for Psychiatry in Munich.
• Signature of our third business contract with a pharma/biopharma company
• Signature of our second “white biotech*” deal.
• Publication of our third and fourth experimentally validated models. (Creutzfeld-Jacob [prion] disease and prophilaxy, and Müllerian duct regression).

*Europabio definition. White Biotechnology is an emerging field within modern biotechnology that serves industry. It uses living cells like moulds, yeasts or bacteria, as well as enzymes to produce goods and services.